InnoTherapy (Korea) Today
| 246960 Stock | KRW 8,430 130.00 1.57% |
Performance0 of 100
| Odds Of DistressLess than 32
|
InnoTherapy is trading at 8430.00 as of the 22nd of November 2024, a 1.57 percent increase since the beginning of the trading day. The stock's open price was 8300.0. InnoTherapy has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for InnoTherapy are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of November 2023 and ending today, the 22nd of November 2024. Click here to learn more.
InnoTherapy, Inc., engages in the development and sale of medical sealant products in South Korea. The company was founded in 2010 and is headquartered in Seoul, South Korea. InnoTherapy is traded on Korean Securities Dealers Automated Quotations in South Korea. The company has 5.04 M outstanding shares. More on InnoTherapy
Moving together with InnoTherapy Stock
| 0.74 | 102940 | Kolon Life Science | PairCorr |
| 0.69 | 074430 | Aminologics CoLtd | PairCorr |
| 0.84 | 023910 | Daihan Pharmaceutical | PairCorr |
| 0.86 | 047920 | HLB Pharmaceutical | PairCorr |
| 0.78 | 330350 | Withuspharmaceutical | PairCorr |
Moving against InnoTherapy Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
InnoTherapy Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. InnoTherapy's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding InnoTherapy or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Founder CEO | Moonsue Lee |
| Thematic Ideas | (View all Themes) |
| Business Concentration | Health Management, Management, Pharmaceuticals (View all Sectors) |
InnoTherapy (246960) is traded on KOSDAQ in Korea and employs 26 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 44.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate InnoTherapy's market, we take the total number of its shares issued and multiply it by InnoTherapy's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. InnoTherapy has 5.04 M outstanding shares.
InnoTherapy has accumulated about 1.03 B in cash with (3.98 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 375.11.
Check InnoTherapy Probability Of Bankruptcy
Ownership AllocationThe market capitalization of InnoTherapy is W44.19 Billion. InnoTherapy secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check InnoTherapy Ownership Details
InnoTherapy Risk Profiles
Although InnoTherapy's alpha and beta are two of the key measurements used to evaluate InnoTherapy's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.11 | |||
| Standard Deviation | 1.52 | |||
| Variance | 2.3 | |||
| Risk Adjusted Performance | (0.09) |
InnoTherapy Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in InnoTherapy without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
InnoTherapy Corporate Executives
Elected by the shareholders, the InnoTherapy's board of directors comprises two types of representatives: InnoTherapy inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InnoTherapy. The board's role is to monitor InnoTherapy's management team and ensure that shareholders' interests are well served. InnoTherapy's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InnoTherapy's outside directors are responsible for providing unbiased perspectives on the board's policies.
| HaeShin Lee | Founder CTO | Profile | |
| In Moon | COO CFO | Profile |
Other Information on Investing in InnoTherapy Stock
InnoTherapy financial ratios help investors to determine whether InnoTherapy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoTherapy with respect to the benefits of owning InnoTherapy security.